Study of Motexafin Gadolinium and Docetaxel for Advanced Cancer

NCT00120939 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

25

Enrollment

INDUSTRY

Sponsor class

Conditions

Breast Neoplasms
Ovarian Neoplasms
Prostatic Neoplasms
Lung Neoplasms
Gastrointestinal Neoplasms

Interventions

DRUG: Motexafin Gadolinium

Sponsor

Pharmacyclics LLC.